The NM_000156.6:c.202G>T variant in GAMT is predicted to result in the missense substitution of glycine by cysteine at amino acid 68 (p.Gly68Cys). The variant has been reported in homozygosity in a proband and sibling with clinical symptoms consistent with GAMT deficiency (PM3_Supporting). The proband has absent creatine peak and guanidinoacetate peak on brain MRS. Urine guanidinoacetate levels were elevated in all patients and were between 1.1 and 12 times above the upper limit of reference range, but specific values for each patient were not provided (PP4_Moderate) (PMID: 24415674). This variant is absent in gnomAD v4.1.0. (PM2_Supporting). The computational predictor REVEL gives a score of 0.994 which is above the threshold of 0.932, evidence that correlates with impact to GAMT function at the strong level (PMID: 36413997) (PP3_Strong). This variant was shown to result in undetectable GAMT enzymatic activity when transfected into GAMT-deficient fibroblasts (PMID: 24415674) (PS3_Supporting). There is a ClinVar entry for this variant (Variation ID: 2446456). In summary, this variant meets criteria to be classified as likely pathogenic for guanidinoacetate methyltransferase (GAMT) deficiency. GAMT-specific ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiencies Variant Curation Expert Panel (CCDS VCEP) (Specifications version 2.0.0): PP3_Strong, PP4_Moderate, PS3_Supporting, PM2_Supporting, PM3_Supporting (Classification approved by the ClinGen Cerebral Creatine Deficiencies Variant Curation Expert Panel on October 15, 2025